Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 218,041 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 218,041 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22. Following the transaction, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,345,374.98. This represents a 19.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Eric Venker also recently made the following trade(s):

• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $10.56 on Friday. The company has a market cap of $7.69 billion, a PE ratio of 1.87 and a beta of 1.25. The business has a 50-day simple moving average of $11.34 and a two-hundred day simple moving average of $11.58. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -1.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. boosted its holdings in Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after acquiring an additional 1,948 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences during the third quarter worth about $35,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Roivant Sciences during the fourth quarter worth about $39,000. US Bancorp DE lifted its holdings in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ROIV shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.